|
Androgenetic Alopecia Treatment Market |
Androgenetic alopecia (AGA) is one of the most common chronic skin conditions seen by dermatologists around the world. It is characterised by progressive hair loss, particularly of scalp hair, and has distinct patterns of loss in women versus men, but the central scalp is most severely affected in both genders. It frequently begins around puberty and is known to have an impact on self-esteem and an individual's quality of life. Despite the high prevalence of AGA, approved treatment options are limited. In addition to the limited pharmacologic treatments, there are a plethora of over-the-counter products that claim to be effective in restoring hair in androgenetic alopecia.
According To Coherent Market Insights "The global androgenetic alopecia treatment market is estimated to be valued at US$ 1,607.47 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027)."
Androgenetic alopecia is very common, and the problem is poor cosmesis in both males and females. The condition is frequently seen in dermatology clinics. Most patients are embarrassed to seek medical attention and frequently turn to the internet for solutions. Patient education is essential in the
Androgenetic alopecia treatment of this disorder. The pharmacist is uniquely placed to educate the general public about the causes and treatment of androgenetic alopecia. While some men experience complete baldness within a few years, others may experience patterned scalp thinning. Women typically lose hair on the crown and rarely go completely bald.
When hair falls out, the scalp is exposed to UV rays from the sun, and there is mounting evidence that this increases the risk of actinic keratosis. More importantly, androgenetic alopecia is linked to an increased risk of adverse cardiac events in men. Androgenetic alopecia has been linked to polycystic ovarian disease in women. Despite the availability of a variety of medications and hair transplants, neither works well and the outcomes are unpredictable. For patients who are unconcerned about their hair thinning, simply assuring them that it is a benign disorder is sufficient. Clinicians, nurses, and pharmacists must collaborate to educate patients about this troubling issue.
Comments
Post a Comment